2016 American Transplant Congress
The Incidence, Risk Factors and Clinical Course of De Novo Hepatitis B Infection in Pediatric Living Donor Liver Transplantation.
Aim: We evaluated the incidence, risk factors and clinical course of liver transplanted pediatric patients with de novo hepatitis B infection and the clinical course…2016 American Transplant Congress
Hepatitis B Immune Globulin Withdrawal in HBsAg Positive Liver Transplant Patients.
Introduction: Liver transplantation for chronic hepatitis B virus (HBV) is associated with a high recurrence rate of HBV post-transplant without the use of prophylaxis. The…2016 American Transplant Congress
Evaluation of Long Term Outcome After Living Donor Liver Transplantation in Sequential 653 Recipients with or without Viral Infection: Is HBV & HCV Co-Infection Better Than the Monoinfection? A Single Center Retrospective Analysis.
Organ Transplantation, China Medical University Hospital, Taichung, Taiwan.
Background:End-stage liver disease secondary to HBV and HCV coinfection is not uncommon in Asia.However,long term outcome of such patients after living donor liver transplantation (LDLT)…2016 American Transplant Congress
Limited Hepatitis B Immune Globulin Following Liver Transplant for Hepatitis B.
Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, MN.
IntroductionThe hypothesis of this study was that the long-term outcomes in liver transplant (LTx) patients with hepatitis B virus (HBV) who were treated with nucleos(t)ide…2016 American Transplant Congress
Sirolimus Regimen and Viral Serology as Risk Factors for Outcomes of Adult Kidney Transplants: 14-Year Cumulative Data in the United States.
Department of Medicine, Univ. of Florida, College of Medicine, Gainesville, FL.
BACKGROUND: The relative risks for patient mortality, graft loss and malignancy in the five years following kidney-only transplant (KT) based on sirolimus (SRL) regimen at…2016 American Transplant Congress
Donors with Isolated Anti-HBc (“HBcAb Only”) Antibodies: True Evidence for Past Infection or Laboratory Artifact? Toward a Simple Confirmatory Test for HBcAb.
Use of organs from donors positive for hepatitis B virus (HBV) markers may safely expand the donor pool. Recently the American Society of Transplantation expert…2016 American Transplant Congress
An Economical and Effective Vaccination Program in Patients Transplanted for Hepatitis B Virus Related Liver Diseases: A Prospective Study.
Aims: To prospectively investigate the efficacy and safety of procedural HBV vaccination in patients transplanted for HBV related liver diseases for prevention of hepatitis B…2016 American Transplant Congress
The Effect of Rituximab on Hepatitis B Reactivation in Kidney Transplant Recipients with Resolved Hepatitis B.
Background: Hepatitis B virus (HBV) reactivation is a well-known complication of immunosuppressive therapy in resolved HBV (hepatitis B surface antigen [HBsAg] negative and hepatitis B…2016 American Transplant Congress
Long-Term Liver Function of Deceased Liver Transplantation Using Hepatitis B Surface Antigen Positive Grafts.
Background: Deceased donors with hepatitis B [HBs Ag(+)] were not recommended to recover the livers for liver transplantation. However, in endemic area of hepatitis B…2015 American Transplant Congress
Replacement of Lamivudine By Telbivudine to Improve Renal Function for Post-Transplant Hepatitis B Patients – A Randomized Clinical Trial
Background: Lamivudine is one of the anti-hepatitis B virus (HBV) agents to prevent HBV recurrence after transplantation because lamivudine is safe for long-term use. However,…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- Next Page »